Veracyte market cap is $2.9 b, and annual revenue was $120.37 m in FY 2019

Veracyte Net income (Q3, 2020)-4.1 M

Veracyte EBIT (Q3, 2020)-4.1 M

Veracyte Cash, 30-Sept-2020345.1 M

Veracyte EV2.6 B

Veracyte revenue was $120.37 m in FY, 2019 which is a 30.8% year over year increase from the previous period.

Veracyte revenue breakdown by business segment: 89.2% from Testing Revenue, 6.7% from Biopharmaceutical Revenue and 4.1% from Other

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Revenue | 72.0m | 92.0m | 120.4m |

| 28% | 31% | |

## Cost of goods sold | 28.2m | 33.1m | 36.5m |

## Gross profit | 43.8m | 58.9m | 83.8m |

| 61% | 64% | 70% |

## Sales and marketing expense | 32.3m | 41.3m | 53.7m |

## R&D expense | 13.9m | 14.8m | 14.9m |

## General and administrative expense | 23.1m | 24.0m | 29.0m |

## Operating expense total | 70.3m | 81.2m | 99.0m |

## Depreciation and amortization | 1.1m | 1.1m | 1.4m |

## EBIT | (26.5m) | (22.2m) | (15.1m) |

| (37%) | (24%) | (13%) |

## Interest expense | 4.9m | 2.0m | 677.0k |

## Net Income | (31.0m) | (23.0m) | (12.6m) |

## EPS | (0.9) | (0.6) | (0.3) |

USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 20.0m | 22.8m | 23.5m | 29.5m | 30.1m | 31.0m | 31.1m | 20.7m | 31.1m |

## Cost of goods sold | 7.9m | 8.2m | 8.3m | 8.5m | 8.8m | 9.1m | 12.2m | 7.7m | |

## Gross profit | 12.2m | 14.5m | 15.2m | 21.0m | 21.4m | 21.9m | 18.9m | 13.0m | |

| 61% | 64% | 65% | 71% | 71% | 71% | 61% | 63% | |

## Sales and marketing expense | 11.5m | 9.6m | 10.1m | 12.5m | 13.9m | 13.1m | 17.6m | 10.7m | 11.0m |

## R&D expense | 3.7m | 4.6m | 3.4m | 3.4m | 3.3m | 3.6m | 4.4m | 4.2m | 4.0m |

## General and administrative expense | 5.6m | 5.9m | 5.7m | 6.9m | 6.9m | 6.6m | 7.8m | 8.0m | 8.5m |

## Operating expense total | 21.1m | 20.4m | 19.5m | 23.1m | 24.5m | 23.6m | 31.1m | 24.1m | 23.5m |

## Depreciation and amortization | 267.0k | 266.0k | 267.0k | 267.0k | 266.0k | 267.0k | 1.3m | 1.3m | 1.3m |

## EBIT | (9.0m) | (5.9m) | (4.3m) | (2.1m) | (3.1m) | (1.8m) | (12.2m) | (11.1m) | (4.1m) |

| (45%) | (26%) | (18%) | (7%) | (10%) | (6%) | (39%) | (53%) | (13%) |

## Interest expense | 448.0k | 481.0k | 498.0k | 303.0k | 235.0k | 58.0k | 55.0k | 65.0k | |

## Income tax expense | |||||||||

## Net Income | (9.2m) | (6.2m) | (4.5m) | (1.9m) | (2.5m) | (730.0k) | (11.7m) | (11.0m) | (4.1m) |

## EPS | (0.3) | (0.2) | (0.1) | 0.0 | 0.0 | 0.0 | (0.2) | (0.2) |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Cash | 33.9m | 78.0m | 159.3m |

## Accounts Receivable | 12.7m | 13.2m | 19.3m |

## Prepaid Expenses | 2.0m | 2.4m | 2.2m |

## Inventories | 5.3m | 3.4m | 6.8m |

## Current Assets | 53.9m | 97.0m | 187.7m |

## PP&E | 9.7m | 8.9m | 8.9m |

## Goodwill | 1.1m | 1.1m | 2.7m |

## Total Assets | 78.7m | 120.6m | 275.2m |

## Accounts Payable | 3.9m | 2.5m | 2.3m |

## Short-term debt | 1.4m | 1.4m | |

## Current Liabilities | 12.0m | 13.1m | 17.5m |

## Long-term debt | 25.2m | 23.9m | 12.2m |

## Total Debt | 25.2m | 25.3m | 13.6m |

## Total Liabilities | 41.4m | 40.9m | 35.8m |

## Common Stock | 34.0k | 41.0k | 50.0k |

## Additional Paid-in Capital | 248.3m | 313.8m | 486.1m |

## Retained Earnings | (211.1m) | (234.1m) | (246.7m) |

## Total Equity | 37.2m | 79.8m | 239.5m |

## Debt to Equity Ratio | 0.7 x | 0.3 x | 0.1 x |

## Debt to Assets Ratio | 0.3 x | 0.2 x | 0 x |

## Financial Leverage | 2.1 x | 1.5 x | 1.1 x |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Net Income | (31.0m) | (23.0m) | (12.6m) |

## Depreciation and Amortization | 3.8m | 3.9m | 4.1m |

## Accounts Receivable | (4.0m) | (452.0k) | (6.2m) |

## Inventories | (1.8m) | 1.9m | (3.4m) |

## Accounts Payable | 1.7m | (1.6m) | (141.0k) |

## Cash From Operating Activities | (23.9m) | (13.5m) | (3.2m) |

## Purchases of PP&E | (1.8m) | (1.9m) | (2.8m) |

## Cash From Investing Activities | (1.2m) | (1.9m) | (42.7m) |

## Long-term Borrowings | (25.7m) | (292.0k) | (25.2m) |

## Cash From Financing Activities | (218.0k) | 59.5m | 127.3m |

## Net Change in Cash | (25.3m) | 44.1m | 81.3m |

## Interest Paid | 2.7m | 1.5m | 332.0k |

## Income Taxes Paid | 21.0k | 79.0k | 35.0k |

USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (9.2m) | (15.4m) | (19.9m) | (1.9m) | (4.4m) | (5.1m) | (11.7m) | (22.7m) | (26.9m) |

## Depreciation and Amortization | 980.0k | 2.0m | 3.0m | 945.0k | 1.9m | 2.8m | 2.0m | 3.9m | 5.9m |

## Accounts Receivable | (482.0k) | (290.0k) | 454.0k | (3.4m) | (6.5m) | (10.4m) | 238.0k | 4.0m | 1.7m |

## Inventories | 767.0k | 2.3m | 1.9m | (366.0k) | (1.7m) | (3.2m) | (376.0k) | (1.3m) | 1.3m |

## Accounts Payable | (510.0k) | (1.9m) | (2.6m) | 1.7m | 1.7m | 2.5m | 5.5m | 122.0k | (534.0k) |

## Cash From Operating Activities | (7.4m) | (10.5m) | (12.3m) | (1.0m) | (3.5m) | (5.0m) | (5.3m) | (13.7m) | (12.0m) |

## Purchases of PP&E | (227.0k) | (761.0k) | (1.4m) | (765.0k) | (1.4m) | (1.7m) | (665.0k) | (1.3m) | (1.9m) |

## Cash From Investing Activities | (227.0k) | (761.0k) | (1.4m) | (749.0k) | (1.4m) | (1.6m) | (665.0k) | (1.3m) | (2.9m) |

## Long-term Borrowings | (71.0k) | (144.0k) | (217.0k) | (12.6m) | (25.1m) | (25.1m) | (100.0k) | ||

## Cash From Financing Activities | 901.0k | 1.1m | 57.7m | (8.4m) | 119.5m | 124.3m | (219.0k) | 3.2m | 200.7m |

## Net Change in Cash | (6.7m) | (10.1m) | 44.0m | (10.2m) | 114.7m | 117.7m | (6.2m) | (11.9m) | 185.8m |

## Interest Paid | 356.0k | 741.0k | 1.2m | 228.0k | 319.0k | 330.0k | 1.0k | 3.0k | 3.0k |

USD | FY, 2017 |
---|---|

## EV/EBIT | -8.1 x |

## EV/CFO | -8.9 x |

## Revenue/Employee | 292.5k |

## Debt/Equity | 0.7 x |

## Debt/Assets | 0.3 x |

## Financial Leverage | 2.1 x |

## P/E Ratio | (7.2) |